Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
Takeda’s Acquisition of NDI-034858 from Nimbus Therapeutics
FibroGen’s Royalty Monetization Financing with NovaQuest Capital Management
Goodwin Procter advised FibroGen, Inc. on the deal. FibroGen, Inc. announced its capped royalty monetization financing with NovaQuest Capital Management. The non-dilutive financing provides FibroGen with...
Alladapt Immunotherapeutics’ $100+ Million Financing Round
Goodwin Procter advised Alladapt Immunotherapeutics Inc. on the deal. Alladapt Immunotherapeutics Inc. announced its $100+ million financing round led by Enavate Sciences, a portfolio company created by...
BridgeBio’s $110 Million Sale of Priority Review Voucher
Goodwin Procter advised BridgeBio on the deal. BridgeBio announced its definitive agreement with an undisclosed purchaser to sell its rare pediatric disease Priority Review Voucher for $110...